



PPD Declares First Quarter Dividend

WILMINGTON, N.C. (March 1, 2010) - PPD, Inc. (Nasdaq: PPDI) today announced that its board of directors declared a cash dividend for the first quarter of 2010 under its annual cash dividend policy. The quarterly cash dividend will equal \$0.15 per share. The record date for the first quarter dividend is March 15, 2010, and the payment date is March 29, 2010. The annual cash dividend policy and the payment of future quarterly cash dividends under that policy are subject to the continuing determination by the board of directors that the policy remains in the best interests of the company's shareholders and in compliance with applicable laws and agreements.

PPD is a leading global contract research organization, celebrating 25 years of providing discovery and development services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 40 countries and more than 10,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and commitment to quality to help clients and partners maximize returns on R&D investments that accelerate the delivery of safe, effective therapeutics. For more information, visit www.ppd.com.

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions about the payment of future cash dividends under the annual dividend policy, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: risks that we may not continue our dividend policy; economic conditions and outsourcing trends in the pharmaceutical, biotechnology and medical device industries and government-sponsored research sector; success in sales growth; loss of or delay in large contracts; high cancellation rates; competition within the outsourcing industry; risks associated with the development and commercialization of drugs, including obtaining regulatory approvals; the ability to attract and retain key personnel; dependence on collaborative relationships; rapid technological advances that make our products and services less competitive; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.

Contacts

Dan Darazsdi
+1 910 558 7915
daniel.darazsdi@ppdi.com

Luke Heagle
+1 910 558 7585
luke.heagle@ppdi.com